Siegfried Holding AG Delivers Record Margins Amid Expansion

Siegfried Holding AG ((CH:SFZN)) has held its Q4 earnings call. Read on for the main highlights of the call.

Siegfried Holding AG’s latest earnings call struck an upbeat tone, showcasing record profitability, expanding margins, and robust cash generation despite currency headwinds and some demand uncertainty. Management leaned into a confident narrative of structural strength, underpinned by strategic U.S. expansion, strong RFP momentum, and clear progress in safety and sustainability.

Steady Revenue Growth and Increasing Scale

Siegfried reported 2025 group sales of CHF 1.33 billion, representing 4.3% growth in local currencies as both Drug Substance and Drug Product rose at the same pace. The second half was again heavier, with roughly 53% of annual revenue booked in H2, underscoring the pronounced seasonality that continues to shape quarterly optics.

Record Profitability and Expanding Margins

Profitability hit new highs as core EBITDA climbed 9.3% year over year to CHF 312.3 million, driving a margin of about 23.5% and lifting core gross profit 7.6% to CHF 354 million. Management framed this as structural improvement rather than a one‑off, reiterating an ambition to keep the core EBITDA margin above 23% into 2026 even when excluding the CHF 7.5 million recovery.

Robust Cash Generation and Flexible Balance Sheet

Operating cash flow jumped about 35% versus the prior year, reflecting better working capital management and the back‑end revenue skew turning into cash. With a CHF 300 million bond issue and a non‑recourse factoring line of CHF 50 million, of which CHF 40 million is used, net debt to EBITDA stood near 1.5x at year‑end and around 1.0x after receivables conversion, leaving ample financial firepower.

Heavy Investment Cycle to Support Future Growth

Siegfried deployed CHF 231 million in tangible and intangible investments in 2025, focused on expanding capacity and adding new capabilities across its network. Management acknowledged that this elevated capex depresses near‑term earnings conversion but expects investment intensity to normalize to a low‑teens percentage of sales as the new assets ramp.

Strategic U.S. Expansion via Noramco/Extractas Deal

The acquisition of Noramco/Extractas marks a major step in building U.S. scale, adding large‑scale CDMO capacity and a broader footprint in a key market. Executives emphasized that the purchase price is below a roughly 10x EBITDA multiple, is expected to contribute to both revenue and profit from day one, and should unlock additional upside as existing capacity is freed and synergies materialize.

Commercial Momentum and Strong RFP Pipeline

Commercially, Siegfried underlined a clear uptick in demand with RFP inflows and wins up about 30% versus 2024 across both Drug Substance and Drug Product. The recent capture of three protein degrader programs in just the last five weeks highlights traction in innovative modalities, bolstering confidence that today’s pipeline will feed tomorrow’s capacity.

Operational Excellence and Quality Milestones

On the operational side, the company reported a 25% improvement in lost‑time injury frequency, evidencing ongoing safety gains across its manufacturing base. Quality credentials were also reinforced, with six of 13 sites now certified under the Class A project, four successful FDA inspections in 2025, and the DINAMIQS unit passing Swissmedic GMP review to begin GMP production.

Sustainability Targets Drive Efficiency Gains

Siegfried highlighted tangible progress on its sustainability roadmap, reporting roughly 50% reductions in CO2 emissions and energy use versus 2020 levels. Management presented these gains as not only meeting ESG expectations but also enhancing long‑term competitiveness through lower resource intensity and improved operational resilience.

One‑Time Recovery Boosts Other Income

Results also benefited from a one‑off CHF 7.5 million recovery related to a fraudulent payment made in 2021, which was booked under other operating income. While this recovery helped the year’s reported figures, management and analysts largely focused on underlying trends, adjusting margin commentary to exclude the exceptional item.

Shareholder Returns and Disciplined Capital Allocation

The board proposed a par value repayment of CHF 0.40 per share, offering a modest cash return while preserving flexibility. Management reiterated a disciplined capital allocation framework that balances shareholder distributions, ongoing organic investment, and selective M&A, stressing that the balance sheet can still support additional deals when value‑accretive opportunities arise.

Exposure to a Large On‑Market Drug Substance Contract

A key watchpoint is a pending customer confirmation for a sizeable on‑market Drug Substance product, with market commentary suggesting an annual scale near CHF 40 million. While this uncertainty led to a cautious 2026 growth outlook for Drug Substance, management underlined that margins are contractually protected, helping to limit the potential bottom‑line impact even if volumes shift.

Persistent Currency Headwinds on Reported Numbers

Foreign‑exchange has been a meaningful drag, with cumulative FX headwinds since 2020 estimated at around CHF 140 million. For 2026, the company expects another roughly 2% negative FX impact on reported revenue, front‑loaded in the first half at close to 2.8%–3%, which may mask underlying local‑currency progress.

Seasonality and Timing Still Distort the Optics

Revenue recognition timing and strong second‑half weighting continue to create volatility in reported quarters and in net working capital. Year‑end invoicing patterns and batch timing can therefore skew cash flows and perceived momentum, making full‑year and multi‑year trends more reliable indicators than single‑quarter snapshots.

Ramp‑Up Effects from Heavy Investment Program

The high investment load in 2025, including new capacity and technologies, has yet to translate fully into earnings, dampening near‑term EBIT conversion. Management signaled that as these assets mature and utilization builds, returns should gradually improve, but investors should expect some lag before the P&L captures the full benefits.

Managing Market Expectations on Growth Pace

Some investors were underwhelmed by the exit‑rate growth in the second half, which management quantified at about 6.5%, below more bullish expectations. Executives attributed part of this gap to project ramp cadence and batch timing rather than demand weakness, arguing that the build‑up in RFPs and new wins better reflects underlying momentum.

New Units Still Early in the Revenue Curve

Emerging growth platforms such as DINAMIQS and the Wisconsin site carry strong development pipelines but currently contribute only modest revenue. With GMP clearances now in hand and further qualifications underway, Siegfried expects more meaningful P&L contributions only over time as these units transition from development work to commercial‑scale production.

Guidance and Outlook: Modest Growth, Firm Margins

Looking ahead to 2026, management guided to low single‑digit group revenue growth, with Drug Product expected to accelerate to high single‑digit growth and Drug Substance limited to low single digits amid contract uncertainty and FX headwinds of about 2%. Despite these pressures, the company aims to maintain a core EBITDA margin above 23%, while the pending Noramco/Extractas deal could provide an additional top‑ and bottom‑line uplift once closed and integrated.

Siegfried’s earnings call painted a picture of a CDMO leaning into its strengths, combining record margins and strong cash generation with disciplined investment and targeted U.S. expansion. While FX, seasonality, and a key contract decision inject some near‑term noise, the underlying trajectory of higher‑quality earnings, growing commercial momentum, and a strengthened balance sheet leaves the company well‑positioned for long‑term value creation.